An observational study in Schizophrenia Relapse Prevention, sponsored by AstraZeneca. Completed at 48 sites in Hungary. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2010-11-17.
Sponsored by AstraZeneca · Observational
The purpose of the study is to determine whether the Seroquel XR treatment for 6 months improve the relapse prevention in schizophrenic outpatients
4,279 studies on the registry are indexed under Recurrence; 988 are open to participants now.
This study's planned enrollment of 1,600 is above the median of 200 across 702 observational studies indexed under Recurrence.
Browse Recurrence studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Psychiatric outpatient clinics
Exclusion Criteria:
Schizophrenic outpatients
Rate of patients remained relapse free after 6 months of treatment
Adherence rate of patients
Quality of Life (QoL )
This study is completed, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca